Business Context and Reporting Period
This Form 8-K is filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on February 4, 2013, reporting events that occurred on January 29, 2013. The company is a medical technology firm incorporated in Delaware with principal executive offices in Eden Prairie, Minnesota.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
- Board Resignation: Dr. William Peters resigned from the Board of Directors on January 29, 2013. The resignation was not based on any disagreement with the Company.
- Director Appointment: Mr. Warren S. Watson was elected to fill the vacancy in Class I on the Board, effective January 29, 2013. Mr. Watson brings over 35 years of medical device experience, including prior roles at Medtronic and Cameron Health.
- Board Size Reduction: On January 16, 2013, the Board reduced its size to seven members, eliminating the vacancy left by Mr. Mark Harvey's resignation in November 2012.
- De-listing Intent: The Company announced its intention to de-list from the official list of the Australian Stock Exchange (ASX) during the first half of 2013.
Guidance, Outlook, and Compensation
Director Compensation: Under the policy effective January 1, 2013, non-employee directors receive a base annual retainer of $55,000, while the Chairman receives $105,000. Mr. Watson is eligible for stock options under the outside director equity compensation policy.
Indemnity Agreements: The Company entered into standard indemnity agreements with both Mr. Watson and Chairman John Erb on January 29, 2013.
Outlook: The filing indicates a strategic shift regarding international listings with the planned de-listing from the ASX. No specific financial guidance or risk factors beyond the governance changes are detailed in this document.
Investor Verification Checklist
- Verify the strategic rationale for de-listing from the Australian Stock Exchange (ASX) and the expected timeline for completion.
- Review the definitive proxy statement (Schedule 14A) filed on July 27, 2012, for full details on the non-employee director compensation program.
- Confirm the impact of the Board composition changes on the company's governance and strategic direction.
- Check subsequent filings for the official completion of the ASX de-listing process.